Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug

Glenmark Pharmaceuticals Ltd announced that its subsidiary, Glenmark Specialty S A (GSSA), has entered into a license agreement with Jiangsu Alphamab Biopharmaceuticals Co and 3D Medicines (Beijing) Co Ltd for KN035 (Envafolimab), a cancer treatment drug. Under the agreement, Glenmark gains the license for KN035 (Envafolimab) in various regions, including India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NeoxlVU
via IFTTT